Bioleap
Bioleap is revolutionizing immunotherapy development through precision biosimulation and next-generation analytics. Their Hybrid-AI platform utilizes detailed mechanistic models to achieve 100x better prediction accuracy with a 20-fold reduction in data requirements. This approach overcomes the limitations of traditional AI and Quantitative Systems Pharmacology (QSP) by integrating siloed data into a single mathematical framework that accounts for biological complexity, enabling more accurate predictions and detailed mechanistic insights. Bioleap's platform accelerates the entire drug development pipeline, from preclinical research by simulating thousands of scenarios, to optimizing patient stratification, refining dosing strategies, and supporting data-driven clinical trials. The company is based in the United Kingdom.
Bioleap
Bioleap is revolutionizing immunotherapy development through precision biosimulation and next-generation analytics. Their Hybrid-AI platform utilizes detailed mechanistic models to achieve 100x better prediction accuracy with a 20-fold reduction in data requirements. This approach overcomes the limitations of traditional AI and Quantitative Systems Pharmacology (QSP) by integrating siloed data into a single mathematical framework that accounts for biological complexity, enabling more accurate predictions and detailed mechanistic insights. Bioleap's platform accelerates the entire drug development pipeline, from preclinical research by simulating thousands of scenarios, to optimizing patient stratification, refining dosing strategies, and supporting data-driven clinical trials. The company is based in the United Kingdom.